You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 14, 2025

Details for Patent: 8,772,497


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,772,497 protect, and when does it expire?

Patent 8,772,497 protects FYCOMPA and is included in two NDAs.

This patent has fifty-three patent family members in twenty-eight countries.

Summary for Patent: 8,772,497
Title:Method for producing 1, 2-dihydropyridine-2-one compound
Abstract: The present inventions provide a method for commercially producing a 1,2-dihydropyridine-2-one compound represented by the following formula (III-a) ##STR00001## wherein the ring A represents an optionally substituted 2-pyridyl group, the ring B represents an optionally substituted phenyl group, and the ring C represents an optionally substituted phenyl group. Further, the invention provides crystals of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one and production processes therefore.
Inventor(s): Arimoto; Itaru (Tokyo, JP), Nagato; Satoshi (Tokyo, JP), Sugaya; Yukiko (Tsukuba, JP), Urawa; Yoshio (Kamisu, JP), Ito; Koichi (Tsukuba, JP), Naka; Hiroyuki (Kamisu, JP), Omae; Takao (Tsukuba, JP), Kayano; Akio (Kamisu, JP), Nishiura; Katsutoshi (Kamisu, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:12/870,507
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,772,497
Patent Claim Types:
see list of patent claims
Compound; Process;
Patent landscape, scope, and claims:

United States Patent 8,772,497: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 8,772,497, issued on July 8, 2014, is a significant patent in the pharmaceutical industry, particularly related to the production of a 1,2-dihydropyridine-2-one compound. This compound is crucial in the formulation of the drug FYCOMPA® (perampanel), used in the treatment of epilepsy. Here, we delve into the scope, claims, and the broader patent landscape surrounding this invention.

Patent Overview

Inventors and Assignee

The patent was invented by Arimoto Itaru, Nagato Satoshi, Sugaya Yukiko, Urawa Yoshio, Ito Koichi, Naka Hiroyuki, Omae Takao, Kayano Akio, and Nishiura Katsutoshi. It is assigned to Eisai R&D Management Co., Ltd., a subsidiary of the Japanese pharmaceutical company Eisai Co., Ltd.[2][4].

Scope of the Patent

Method for Producing 1,2-Dihydropyridine-2-one Compound

The patent describes a method for commercially producing a 1,2-dihydropyridine-2-one compound, specifically the active ingredient in FYCOMPA®. This method involves several steps, including the reaction of compounds represented by specific formulas to produce the desired compound. The patent covers various production methods, crystal forms, and compositions related to this compound[2][4].

Claims of the Patent

Production Methods and Crystal Forms

The patent includes multiple claims that cover different aspects of the production process:

  • Production Methods: The patent outlines several methods (1 to 13) for producing the 1,2-dihydropyridine-2-one compound, including reactions involving specific compounds and conditions[4].
  • Crystal Forms: It also describes various crystal forms (14 to 19) of the compound and methods for their production (20 to 28)[4].
  • Medicament and Composition: The claims extend to the medicament and composition involving the produced compound, including agents (41 to 50)[4].

Patent Expiration and Legal Status

Expiration Date

The patent is set to expire on July 1, 2026. This expiration date is critical as it marks the end of the exclusive rights granted to the patent holder, allowing generic manufacturers to potentially enter the market[2].

Legal Actions and Stay

In anticipation of the patent expiration, Eisai has taken legal actions against generic drug manufacturers who have filed Abbreviated New Drug Applications (ANDAs). These lawsuits have triggered a stay, preventing the FDA from approving any ANDA until May 2026 or until a judgment is made on the validity and infringement of the patents[1].

Patent Landscape

Related Patents

The patent landscape for FYCOMPA® includes multiple patents that protect different aspects of the drug:

  • Patent 6,949,571: This patent, set to expire on May 23, 2025, covers another method for producing the 1,2-dihydropyridine-2-one compound[2].
  • Other Patents: There may be additional patents related to the formulation, dosage form, or manufacturing process of FYCOMPA®, which collectively contribute to the comprehensive protection of the drug.

Patent Scope and Breadth

The breadth of a patent’s scope is crucial in determining its protective strength. A broader patent, such as one with fewer conditions in its claims, is generally harder to design around and thus offers more protection against infringers. The number of claims and the specificity of these claims in Patent 8,772,497 suggest a significant scope that protects the production method and related compositions effectively[3].

Impact on Generic Manufacturers

Generic Drug Manufacturers

Generic manufacturers seeking to produce a generic version of FYCOMPA® must navigate the patent landscape carefully. The expiration of Patent 8,772,497 in 2026 will be a critical milestone, but any ongoing litigation and the presence of other related patents could delay their market entry[1][2].

Conclusion

United States Patent 8,772,497 is a pivotal patent in the protection of FYCOMPA®, a significant drug in the treatment of epilepsy. The patent's scope and claims cover a wide range of production methods and compositions, ensuring robust protection for the inventor and assignee. As the patent approaches its expiration date, the legal landscape and potential generic competition will be closely watched.

Key Takeaways

  • Patent Scope: The patent covers multiple production methods, crystal forms, and compositions related to the 1,2-dihydropyridine-2-one compound.
  • Expiration Date: The patent is set to expire on July 1, 2026.
  • Legal Actions: Eisai has filed lawsuits against generic manufacturers to protect the patent.
  • Related Patents: Other patents, such as Patent 6,949,571, also protect aspects of FYCOMPA®.
  • Impact on Generic Manufacturers: Generic entry is delayed due to ongoing litigation and the patent landscape.

FAQs

What is the main subject of United States Patent 8,772,497?

The main subject of United States Patent 8,772,497 is the method for commercially producing a 1,2-dihydropyridine-2-one compound, which is the active ingredient in the drug FYCOMPA®.

Who are the inventors and assignee of the patent?

The inventors include Arimoto Itaru, Nagato Satoshi, Sugaya Yukiko, Urawa Yoshio, Ito Koichi, Naka Hiroyuki, Omae Takao, Kayano Akio, and Nishiura Katsutoshi. The patent is assigned to Eisai R&D Management Co., Ltd.

What is the expiration date of the patent?

The patent is set to expire on July 1, 2026.

How does the patent protect against generic competition?

The patent protects against generic competition through its broad claims covering various production methods and compositions. Eisai has also filed lawsuits against generic manufacturers to trigger a stay preventing FDA approval of generic versions until the patent expires or a judgment is made.

What other patents are related to FYCOMPA®?

Another related patent is Patent 6,949,571, which covers another method for producing the 1,2-dihydropyridine-2-one compound and is set to expire on May 23, 2025.

How does the breadth of the patent affect its protective strength?

A broader patent with fewer conditions in its claims is generally harder to design around and thus offers more protection against infringers. The number of claims and specificity in Patent 8,772,497 suggest a significant scope that protects the production method and related compositions effectively.

Sources

  1. Catalyst Pharmaceuticals INC: Common Stock, IPO Supplement, January 4, 2024.
  2. Drugs.com: Generic Fycompa Availability.
  3. Boston University Law: The Ways We've Been Measuring Patent Scope Are Wrong.
  4. Google Patents: US8772497B2 - Method for producing 1, 2-dihydropyridine-2-one compound.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 8,772,497

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Catalyst Pharms FYCOMPA perampanel SUSPENSION;ORAL 208277-001 Apr 29, 2016 RX Yes Yes 8,772,497 ⤷  Try for Free Y ⤷  Try for Free
Catalyst Pharms FYCOMPA perampanel TABLET;ORAL 202834-001 Oct 22, 2012 RX Yes No 8,772,497 ⤷  Try for Free Y ⤷  Try for Free
Catalyst Pharms FYCOMPA perampanel TABLET;ORAL 202834-002 Oct 22, 2012 RX Yes No 8,772,497 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,772,497

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-198709Jul 6, 2004

International Family Members for US Patent 8,772,497

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1764361 ⤷  Try for Free PA2013017 Lithuania ⤷  Try for Free
European Patent Office 1764361 ⤷  Try for Free C20130021 00081 Estonia ⤷  Try for Free
European Patent Office 1764361 ⤷  Try for Free PA2013017,C1764361 Lithuania ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.